Allogeneic T-cell therapy for Epstein-Barr virus-positive posttransplant lymphoproliferative disease: long-term follow-up.

摘要

Epstein-Barr virus (EBV)-assodated posttransplant lymphoproliferative disease (PTLD) is an important cause of morbidity and mortality in transplant patients. EBV-spedfic cytotoxic T-cell line (CTL) that are in vitro grown and donor derived have been used to prevent and treat EBV-positive PTLD in hematopoietic stem-cell transplant recipients (1)'. However, donor-derived T cells are neither generally available nor appropriate for PTLD arising after solid organ transplantation. Furthermore, although monitoring EBV load in blood may indicate a risk of PTLD after hematopoietic stem-cell transplant, allowing time for CTL preparation, this monitoring gives less convincing results after solid organ transplantation. Additionally, the alternative strategy of generating autologous CTL after PTLD diagnosis often produces unacceptable delays in treatment.